All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
What are the pros and cons of bispecific antibodies and CAR T-cell therapies in myeloma?
Featured:
Mohamad MohtyDuring the 20th International Myeloma Society Annual Meeting 2023, the Multiple Myeloma Hub was pleased to speak to Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR. We asked, What are the pros and cons of bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies in myeloma?
What are the pros and cons of bispecific antibodies and CAR T-cell therapies in myeloma?
In this video interview, Mohamad Mohty opens by discussing the latest developments and approvals for CAR T-cell and bispecific antibody therapies for the treatment of relapsed/refractory multiple myeloma. Mohty goes on to discuss the considerations for the use of each type of agent, including manufacturing times, commercial availability, and the associated adverse events. This interview concludes with a look towards the future myeloma treatment landscape, and how these treatments may be sequenced and combined, and the impact this may have on patient outcomes.
Your opinion matters
Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?